Increasing prevalence of metastatic castration-resistant prostate cancer in a managed care population in the United States

ConclusionThis study found increasing prevalence of mCRPC in an insured patient population during the 8-year period, coupled with stable incidence, validating that patients with the disease are living longer. With the addition of androgen receptor –directed therapies and poly(ADP-ribose) polymerase inhibitors in recent years, this trend will likely continue.
Source: Cancer Causes and Control - Category: Cancer & Oncology Source Type: research